SG11202007414XA - Osimertinib for use in the treatment of non-small cell lung cancer - Google Patents
Osimertinib for use in the treatment of non-small cell lung cancerInfo
- Publication number
- SG11202007414XA SG11202007414XA SG11202007414XA SG11202007414XA SG11202007414XA SG 11202007414X A SG11202007414X A SG 11202007414XA SG 11202007414X A SG11202007414X A SG 11202007414XA SG 11202007414X A SG11202007414X A SG 11202007414XA SG 11202007414X A SG11202007414X A SG 11202007414XA
- Authority
- SG
- Singapore
- Prior art keywords
- osimertinib
- treatment
- lung cancer
- small cell
- cell lung
- Prior art date
Links
- 208000002154 non-small cell lung carcinoma Diseases 0.000 title 1
- DUYJMQONPNNFPI-UHFFFAOYSA-N osimertinib Chemical compound COC1=CC(N(C)CCN(C)C)=C(NC(=O)C=C)C=C1NC1=NC=CC(C=2C3=CC=CC=C3N(C)C=2)=N1 DUYJMQONPNNFPI-UHFFFAOYSA-N 0.000 title 1
- 229960003278 osimertinib Drugs 0.000 title 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
- A61K31/36—Compounds containing methylenedioxyphenyl groups, e.g. sesamin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/243—Platinum; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Inorganic Chemistry (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862629166P | 2018-02-12 | 2018-02-12 | |
| PCT/EP2019/053311 WO2019155059A1 (en) | 2018-02-12 | 2019-02-11 | Osimertinib for use in the treatment of non-small cell lung cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202007414XA true SG11202007414XA (en) | 2020-09-29 |
Family
ID=65443828
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202007414XA SG11202007414XA (en) | 2018-02-12 | 2019-02-11 | Osimertinib for use in the treatment of non-small cell lung cancer |
Country Status (15)
| Country | Link |
|---|---|
| US (4) | US20200368231A1 (ko) |
| EP (1) | EP3752153A1 (ko) |
| JP (2) | JP2021513517A (ko) |
| KR (1) | KR20200119243A (ko) |
| CN (2) | CN111683663A (ko) |
| AU (2) | AU2019219304A1 (ko) |
| BR (1) | BR112020015507A2 (ko) |
| CA (1) | CA3090010A1 (ko) |
| EA (1) | EA202091841A1 (ko) |
| IL (1) | IL276406A (ko) |
| MA (1) | MA51823A (ko) |
| MX (1) | MX2020008395A (ko) |
| SG (1) | SG11202007414XA (ko) |
| TW (1) | TW201941773A (ko) |
| WO (1) | WO2019155059A1 (ko) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110433296A (zh) * | 2019-08-16 | 2019-11-12 | 哈尔滨医科大学 | 一种19f-mr/荧光多模式分子成像及载药的诊疗一体化纳米探针及制备方法和应用 |
| CN114980883A (zh) * | 2020-01-20 | 2022-08-30 | 阿斯利康(瑞典)有限公司 | 用于治疗癌症的表皮生长因子受体酪氨酸激酶抑制剂 |
| WO2022120197A1 (en) * | 2020-12-03 | 2022-06-09 | Emory University | Combinations of epidermal growth factor receptor inhibitors and sterol regulatory element-binding protein inhibitors for uses in cancer therapies |
| CN114917231A (zh) * | 2022-05-27 | 2022-08-19 | 杭州师范大学 | β-榄香稀和奥希替尼药物组合在制备抗肺癌药物上的应用 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK3333161T3 (da) | 2011-07-27 | 2020-05-18 | Astrazeneca Ab | 2-(2,4,5-substitueret anilin)-pyrimidinderivater som egfr-modulatorer, der er anvendelige til behandling af cancer |
| GB201400034D0 (en) * | 2014-01-02 | 2014-02-19 | Astrazeneca Ab | Pharmaceutical Compositions comprising AZD9291 |
| CA2959775A1 (en) * | 2014-09-08 | 2016-03-17 | Yeda Research And Development Co. Ltd. | Compositions and methods for treating cancer resistant to a tyrosine kinase inhibitor (tki) |
| JP6911019B2 (ja) * | 2016-05-17 | 2021-07-28 | 公益財団法人がん研究会 | Ｅｇｆｒ−ｔｋｉ耐性を獲得した肺癌の治療薬 |
-
2019
- 2019-02-11 CA CA3090010A patent/CA3090010A1/en active Pending
- 2019-02-11 CN CN201980012384.XA patent/CN111683663A/zh active Pending
- 2019-02-11 BR BR112020015507-1A patent/BR112020015507A2/pt unknown
- 2019-02-11 AU AU2019219304A patent/AU2019219304A1/en not_active Abandoned
- 2019-02-11 KR KR1020207022313A patent/KR20200119243A/ko active Search and Examination
- 2019-02-11 EA EA202091841A patent/EA202091841A1/ru unknown
- 2019-02-11 WO PCT/EP2019/053311 patent/WO2019155059A1/en unknown
- 2019-02-11 EP EP19705720.1A patent/EP3752153A1/en active Pending
- 2019-02-11 JP JP2020541872A patent/JP2021513517A/ja active Pending
- 2019-02-11 SG SG11202007414XA patent/SG11202007414XA/en unknown
- 2019-02-11 CN CN202310971255.1A patent/CN116870008A/zh active Pending
- 2019-02-11 MA MA051823A patent/MA51823A/fr unknown
- 2019-02-11 TW TW108104348A patent/TW201941773A/zh unknown
- 2019-02-11 MX MX2020008395A patent/MX2020008395A/es unknown
- 2019-02-11 US US16/968,912 patent/US20200368231A1/en not_active Abandoned
-
2020
- 2020-07-30 IL IL276406A patent/IL276406A/en unknown
-
2021
- 2021-10-27 US US17/512,153 patent/US20220184076A1/en not_active Abandoned
-
2022
- 2022-05-05 AU AU2022203007A patent/AU2022203007A1/en active Pending
-
2023
- 2023-03-28 US US18/191,219 patent/US20230226059A1/en not_active Abandoned
- 2023-05-26 JP JP2023087054A patent/JP2023116537A/ja active Pending
-
2024
- 2024-01-16 US US18/413,349 patent/US20240156815A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP3752153A1 (en) | 2020-12-23 |
| CN116870008A (zh) | 2023-10-13 |
| US20200368231A1 (en) | 2020-11-26 |
| US20230226059A1 (en) | 2023-07-20 |
| MA51823A (fr) | 2021-05-19 |
| TW201941773A (zh) | 2019-11-01 |
| MX2020008395A (es) | 2020-09-21 |
| JP2021513517A (ja) | 2021-05-27 |
| BR112020015507A2 (pt) | 2021-01-26 |
| CN111683663A (zh) | 2020-09-18 |
| AU2022203007A1 (en) | 2022-05-26 |
| KR20200119243A (ko) | 2020-10-19 |
| AU2019219304A1 (en) | 2020-09-24 |
| WO2019155059A1 (en) | 2019-08-15 |
| US20240156815A1 (en) | 2024-05-16 |
| US20220184076A1 (en) | 2022-06-16 |
| EA202091841A1 (ru) | 2020-10-28 |
| CA3090010A1 (en) | 2019-08-15 |
| JP2023116537A (ja) | 2023-08-22 |
| IL276406A (en) | 2020-09-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1256283A1 (zh) | 治療癌症有用的二氫咪唑並吡嗪酮衍生物 | |
| ZA201807810B (en) | Adenosine derivatives for use in the treatment of cancer | |
| IL276406A (en) | Osimertinib for use in the treatment of non-small cell lung cancer | |
| IL266198A (en) | Liposomal formulation for use in cancer treatment | |
| HK1252370A1 (zh) | 用於治療非小細胞肺癌的治療方法和組合物 | |
| IL262656A (en) | Nanoliposomal irinotecan for use in the treatment of small cell lung cancer | |
| HUE054998T2 (hu) | Kombinációs terápiák emlõrák kezelésében való alkalmazásra | |
| EP3531830A4 (en) | METHODS AND COMPOSITIONS FOR IDENTIFICATION AND TREATMENT OF PATIENTS WITH SMALL CELL LUNG CANCER | |
| LT3405213T (lt) | Bakteriniai šešėliai, skirti panaudoti vėžio gydyme | |
| ZA202107342B (en) | Chiauranib for treatment of small cell lung cancer | |
| PT3580567T (pt) | Método para o diagnóstico in vitro do cancro do pulmão | |
| IL253933A0 (en) | History of pyrimidine use in the treatment of cancer | |
| EP3440052C0 (en) | COMPOUNDS FOR USE IN THE TREATMENT OF CANCER | |
| IL269121A (en) | Usl-311 for use in the treatment of cancer | |
| GB201514015D0 (en) | Novel pyridazinones and their use in the treatment of cancer | |
| IL289371A (en) | Methylthioninium for use in the treatment of synaptopathies | |
| ZA202006886B (en) | R-fadrozole for use in the treatment of aldostonerism | |
| EP3891123A4 (en) | OLIGO-BENZAMIDE ANALOGS AND THEIR USE IN THE TREATMENT OF CANCER | |
| ZA202001435B (en) | Abx196 for use in the treatment of bladder cancer | |
| HK1245659A1 (zh) | 用於治療神經變性的細胞療法 | |
| HK1245332A1 (zh) | 用於治療神經變性的細胞療法 | |
| HK1246145A1 (zh) | 用於治療神經變性的細胞療法 |